Enliven Therapeutics Inc. has divulged Raf kinase inhibitors reported to be useful for the treatment of cancer. An exemplified compound (Ex 5 [isomer B] pg 130) inhibited ERK phosphorylation in human melanoma A-375 cells (IC50=12.4 nM) in ELISA assays.
Researchers at Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM) and Université Côte d'Azur have divulged amidinourea derivatives reported to be useful for the treatment of cancer, in particular for BRAF inhibitor-resistant melanoma.
Scientists at Aten Porus Lifesciences Pvt Ltd. and Avammune Therapeutics Inc. have synthesized double-stranded RNA-specific adenosine deaminase (ADAR; ADAR1; IFI-4) inhibitors reported to be useful for the treatment of cancer.
CDR-Life Inc. has expanded its pipeline of novel T-cell engagers (TCE) with the addition of CDR-813 and CDR-505. CDR-813 is a highly potent and selective TCE candidate targeting tumors expressing PRAME (preferentially expressed antigen in melanoma) in HLA-A*02:01 patients.
Odimma Therapeutics SAS has developed ODI-2001, a new biological from the combination of neoantigen-expressing DNA vector, an anti-CTLA-4 antibody and an attenuated poxvirus with the aim of increasing the immune response against tumors.
In an indication with few treatment options for patients who are running out of time, Replimune Group Inc. revealed positive top-line results of its lead candidate, RP-1 (vusolimogene oderparepvec), in anti-PD-1-failed melanoma. Data from the phase I/II Ignyte study of RP-1 plus Opdivo (nivolumab, Bristol Myers Squibb Co.) showed the treatment hit the primary endpoint with a 12-month overall response rate of 33.6% and a median duration of response of more than 35 months.
Meliora Therapeutics Inc. has patented cyclin-dependent kinase 11 (CDK11) inhibitors and apoptosis inducers reported to be useful for the treatment of breast cancer and melanoma.
Oncohost Ltd. provided new details on a novel application for its proteomic pattern analysis technology at Biomed Israel last week. While its initial development focused on using a single blood sample to guide selection of first-line immunotherapy for cancer based on likelihood of response, the Prophet platform now also predicts severe adverse immune-related events, Oncohost CEO Ofer Sharon told BioWorld.
Researchers from the University of Colorado presented preclinical data for the myeloid leukemia cell differentiation protein Mcl-1 inhibitor S-64315, currently in phase I clinical development for the treatment of hematologic cancers.
Kinesin-like protein KIFC1 plays a role in the clustering of centrosomes in cancer cells and is being investigated in some types of cancer, concretely in melanoma.
